HLB Life Science Co., Ltd. (KOSDAQ:067630)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,160.00
+80.00 (2.60%)
Aug 14, 2026, 3:30 PM KST

HLB Life Science Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
51,51245,75232,77197,99099,59153,494
Revenue Growth
46.49%39.61%-66.56%-1.61%86.17%-41.73%
Gross Profit
-1,657-721.6-3,634-925.04-3,222-5,661
Operating Income
-21,816-21,035-19,984-25,493-19,950-18,329
Net Income
-50,452-99,7946,138-5,983-54,277-49,152
Earnings Per Share
-413.68-818.7455.00-59.00-537.56-494.76
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
19,74813,87879,56678,860131,989139,961
Total Debt
164,066160,357123,783166,578147,4734,621
Net Cash (Debt)
-144,318-146,479-44,217-87,718-15,484135,340
Net Cash Growth
------7.71%
Net Cash Per Share
-1183.35-1201.75-396.21-861.84-153.361362.33

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-23,493-22,933-32,005-10,016-29,744-14,084
Capital Expenditures
-19,536-25,582-27,296-20,618-10,676-2,421
Free Cash Flow
-43,030-48,515-59,301-30,634-40,420-16,505
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-3.22%-1.58%-11.09%-0.94%-3.23%-10.58%
Operating Margin
-42.35%-45.98%-60.98%-26.02%-20.03%-34.26%
Pretax Margin
-97.56%-219.81%11.14%-6.64%-61.09%-100.24%
Profit Margin
-97.94%-218.12%18.73%-6.11%-54.50%-91.88%
FCF Margin
-83.53%-106.04%-180.96%-31.26%-40.59%-30.85%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--198.66---
PS Ratio
7.4710.3237.2111.9010.8222.23